The KRAS-G12C inhibitor: activity and resistance
Related Experiment Video
Updated: Oct 21, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Jiao Liu1, Rui Kang2, Daolin Tang3,4
1The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Abstract:
Although it has long been deemed "undruggable", with the development of drugs specifically binding the KRAS-G12C mutant protein, clinical trials that directly inhibit oncogenic RAS have recently made promising improvements. In particular, the covalent KRAS-G12C inhibitors sotorasib and adagrasib are used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS-G12C mutations. Unfortunately, the vast majority of patients do not respond to KRAS-G12C inhibitor therapy, mainly due to intrinsic or acquired resistance caused by cellular, molecular, and genetic mechanisms. Improving the understanding of drug response in the tumor microenvironment may continue to promote the design, testing, and clinical application of KRAS-G12C inhibitors.
Insights
Targeting KRAS-G12C mutations in non-small cell lung cancer (NSCLC) with new drugs shows promise. However, most patients don't respond due to resistance, highlighting the need to study the tumor microenvironment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The KRAS-G12C mutation is a key driver in certain cancers, including non-small cell lung cancer (NSCLC).
- Development of targeted therapies, such as covalent KRAS-G12C inhibitors (sotorasib, adagrasib), has offered new treatment avenues for advanced NSCLC.
- Despite initial successes, a significant proportion of patients exhibit primary or acquired resistance to these inhibitors.
Discussion:
- Resistance mechanisms are multifaceted, involving cellular, molecular, and genetic factors.
- Understanding the tumor microenvironment's role is crucial for deciphering drug response and resistance patterns.
- Investigating resistance pathways can identify biomarkers and alternative therapeutic strategies.
Key Insights:
- Targeted inhibition of KRAS-G12C represents a significant advancement in NSCLC treatment.
- Intrinsic and acquired resistance significantly limit the efficacy of current KRAS-G12C inhibitors.
- The tumor microenvironment is a critical determinant of patient response to KRAS-G12C targeted therapy.
Outlook:
- Further research into resistance mechanisms is essential for improving patient outcomes.
- Optimizing KRAS-G12C inhibitor therapy may involve combination strategies or novel drug development.
- Translational studies focusing on the tumor microenvironment will guide future clinical applications and drug design.
